Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYTOCHROME-P450 3A' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 77 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Mittal, N; Thompson, JF; Kato, T; Tzakis, AG
      Tacrolimus and diarrhea: Pathogenesis of altered metabolism

      PEDIATRIC TRANSPLANTATION
    2. Iida, N; Takara, K; Ohmoto, N; Nakamura, T; Kimura, T; Wada, A; Hirai, M; Sakaeda, T; Okumura, K
      Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    3. Imamura, Y; Shimizu, K; Yamashita, F; Yamaoka, K; Takakura, Y; Hashida, M
      Transport characteristics of ebastine and its metabolites across human intestinal epithelial Caco-2 cell monolayers

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    4. Ishikawa, M; Fujita, R; Furusawa, S; Takayanagi, M; Sasaki, K; Satoh, S
      Circumvention of acquired resistance to doxorubicin in K562 human leukemiacells by oxatomide

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    5. Wasan, KM
      Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems

      DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
    6. Johnson, TN; Tanner, MS; Taylor, CJ; Tucker, GT
      Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    7. Zhu, B; Ou-Yang, DS; Cheng, ZN; Huang, SL; Zhou, HH
      Single plasma sampling to predict oral clearance of CYP3A probe midazolam

      ACTA PHARMACOLOGICA SINICA
    8. Delaforge, M; Bouille, C; Jaouen, M; Jankowski, CK; Lamouroux, C; Bensoussan, C
      Recognition and oxidative metabolism of cyclodipeptides by hepatic cytochrome P450

      PEPTIDES
    9. Benet, LZ; Cummins, CL
      The drug efflux-metabolism alliance: biochemical aspects

      ADVANCED DRUG DELIVERY REVIEWS
    10. Agoram, B; Woltosz, WS; Bolger, MB
      Predicting the impact of physiological and biochemical processes on oral drug bioavailability

      ADVANCED DRUG DELIVERY REVIEWS
    11. Wacher, VJ; Salphati, L; Benet, LZ
      Active secretion and enterocytic drug metabolism barriers to drug absorption

      ADVANCED DRUG DELIVERY REVIEWS
    12. Guo, LQ; Taniguchi, M; Chen, QY; Baba, K; Yamazoe, Y
      Inhibitory potential of herbal medicines on human cytochrome P450-mediatedoxidation: Properties of Umbelliferous or Citrus crude drugs and their relative prescriptions

      JAPANESE JOURNAL OF PHARMACOLOGY
    13. van Schaik, RHN; de Wildt, SN; Brosens, R; van Fessem, M; van den Anker, JN; Lindemans, J
      The CYP3A4*3 allele: Is it really rare?

      CLINICAL CHEMISTRY
    14. Greenblatt, DJ; von Moltke, LL; Harmatz, JS; Durol, ALB; Daily, JP; Graf, JA; Mertzanis, P; Hoffman, JL; Shader, RI
      Differential impairment of triazolam and zolpidem clearance by ritonavir

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    15. Liu, Y; Hu, M
      P-glycoprotein and bioavailability-implication of polymorphism

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    16. Odou, P; Levron, JC; Luyckx, M; Brunet, C; Robert, H
      Risperidone drug monitoring - A useful clinical tool?

      CLINICAL DRUG INVESTIGATION
    17. Gerber, JG
      Using pharmacokinetics to optimize antiretroviral drug-drug interactions the treatment of human immunodeficiency virus infection

      CLINICAL INFECTIOUS DISEASES
    18. Cotreau, MM; von Moltke, LL; Beinfeld, MC; Greenblatt, DJ
      Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level

      JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
    19. Ahle, GB; Blum, AL; Martinek, J; Oneta, CM; Dorta, G
      Cushing's syndrome in an 81-year-old patient treated with budesonide and amiodarone

      EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
    20. Ishikawa, M; Fujita, R; Takayanagi, M; Takayanagi, Y; Sasaki, K
      Reversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizole

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    21. Katoh, M; Nakajima, M; Yamazaki, H; Yokoi, T
      Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4

      PHARMACEUTICAL RESEARCH
    22. Kajita, J; Kuwabara, T; Kobayashi, H; Kobayashi, S
      CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes

      DRUG METABOLISM AND DISPOSITION
    23. Choo, EF; Leake, B; Wandel, C; Imamura, H; Wood, AJJ; Wilkinson, GR; Kim, RB
      Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes

      DRUG METABOLISM AND DISPOSITION
    24. Gantenbein, M; Attolini, L; Bruguerolle, B; Villard, PH; Puyoou, F; Durand, A; Lacarelle, B; Hardwigsen, J; Le-Treut, YP
      Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A

      DRUG METABOLISM AND DISPOSITION
    25. Zhang, L; Gorset, W; Washington, CB; Blaschke, TF; Kroetz, DL; Giacomini, KM
      Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system

      DRUG METABOLISM AND DISPOSITION
    26. Sinclair, JF; Szakacs, JG; Wood, SG; Walton, HS; Bement, JL; Gonzalez, FJ; Jeffery, EH; Wrighton, SA; Bement, WJ; Sinclair, PR
      Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    27. Herr, AS; Wochnik, GM; Rosenhagen, MC; Holsboer, F; Rein, T
      Rifampicin is not an activator of glucocorticoid receptor

      MOLECULAR PHARMACOLOGY
    28. Woodland, C; Ito, S; Granvil, CP; Wainer, IW; Klein, J; Koren, G
      Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites

      LIFE SCIENCES
    29. Fontaine, F; de Sousa, G; Burcham, PC; Duchene, P; Rahmani, R
      Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes

      LIFE SCIENCES
    30. Guo, LQ; Taniguchi, M; Xiao, YQ; Baba, K; Ohta, T; Yamazoe, Y
      Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity

      JAPANESE JOURNAL OF PHARMACOLOGY
    31. Mitsunaga, Y; Takanaga, H; Matsuo, H; Naito, M; Tsuruo, T; Ohtani, H; Sawada, Y
      Effect of bioflavonoids on vincristine transport across blood-brain barrier

      EUROPEAN JOURNAL OF PHARMACOLOGY
    32. Wandel, C; Witte, JS; Hall, JM; Stein, CM; Wood, AJJ; Wilkinson, GR
      CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5 '-promoter region polymorphism

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    33. Sakuma, T; Takai, M; Endo, Y; Kuroiwa, M; Ohara, A; Jarukamjorn, K; Honma, R; Nemoto, N
      A novel female-specific member of the CYP3A gene subfamily in the mouse liver

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    34. Kashuba, ADM; Nafziger, AN; Kearns, GL; Leeder, JS; Gotschall, R; Gaedigk, A; Bertino, JS
      Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity

      PHARMACOGENETICS
    35. Sempoux, C; Starkel, P; Stevens, M; Van Den Berge, V; Horsmans, Y
      Cytochrome P450 3A proteins are expressed in B lymphocytes but not in T lymphocytes

      PHARMACOGENETICS
    36. Polli, JW; Jarrett, JL; Studenberg, SD; Humphreys, JE; Dennis, SW; Brouwer, KR; Woolley, JL
      Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

      PHARMACEUTICAL RESEARCH
    37. Raeissi, SD; Hidalgo, IJ; Segura-Aguilar, J; Artursson, P
      Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers

      PHARMACEUTICAL RESEARCH
    38. Soldner, A; Christians, U; Susanto, M; Wacher, VJ; Silverman, JA; Benet, LZ
      Grapefruit juice activates P-glycoprotein-mediated drug transport

      PHARMACEUTICAL RESEARCH
    39. Dintaman, JM; Silverman, JA
      Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS)

      PHARMACEUTICAL RESEARCH
    40. Suter-Eichenberger, R; Boelsterli, UA; Conscience-Egli, M; Lichtensteiger, W; Schlumpf, M
      CYP 450 enzyme induction by chronic oral musk xylene in adult and developing rats

      TOXICOLOGY LETTERS
    41. Gidding, CEM; Meeuwsen-de Boer, GJ; Koopmans, P; Uges, DRA; Kamps, WA; de Graaf, SSN
      Vincristine pharmacokinetics after repetitive dosing in children

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    42. Kudo, S; Ishizaki, T
      Pharmacokinetics of haloperidol - An update

      CLINICAL PHARMACOKINETICS
    43. Min, DI; Ku, YM; Vichiendilokkul, A; Fleckenstein, LL
      A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers

      PHARMACOTHERAPY
    44. Ketter, TA; Frye, MA; Cora-Locatelli, G; Kimbrell, TA; Post, RM
      Metabolism and excretion of mood stabilizers and new anticonvulsants

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    45. Greenblatt, DJ; von Moltke, LL; Daily, JP; Harmatz, JS; Shader, RI
      Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    46. Benet, LZ; Izumi, T; Zhang, YC; Silverman, JA; Wacher, VJ
      Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

      JOURNAL OF CONTROLLED RELEASE
    47. Yuan, R; Flockhart, DA; Balian, JD
      Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam

      JOURNAL OF CLINICAL PHARMACOLOGY
    48. Sandstrom, R; Lennernas, H
      Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats

      DRUG METABOLISM AND DISPOSITION
    49. Surry, DD; McAllister, G; Meneses-Lorente, G; Evans, DC
      High throughput ribonuclease protection assay for the determination of CYP3A mRNA induction in cultured rat hepatocytes

      XENOBIOTICA
    50. Damkier, P; Hansen, LL; Brosen, K
      Effect of fluvoxamine on the pharmacokinetics of quinidine

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    51. Perloff, MD; von Moltke, LL; Cotreau, MM; Greenblatt, DJ
      Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes

      BIOCHEMICAL PHARMACOLOGY
    52. von Moltke, LL; Greenblatt, DJ; Granda, BW; Grassi, JM; Schmider, J; Harmatz, JS; Shader, RI
      Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions

      PSYCHOPHARMACOLOGY
    53. PEREIRA TM; CARLSTEDTDUKE J; LECKNER MC; GUSTAFSSON JA
      IDENTIFICATION OF A FUNCTIONAL GLUCOCORTICOID RESPONSE ELEMENT IN THECYP3A1 IGC2 GENE/

      DNA and cell biology
    54. ITO K; IWATSUBO T; KANAMITSU S; NAKAJIMA Y; SUGIYAMA Y
      QUANTITATIVE PREDICTION OF IN-VIVO DRUG CLEARANCE AND DRUG-INTERACTIONS FROM IN-VITRO DATA ON METABOLISM, TOGETHER WITH BINDING AND TRANSPORT

      Annual review of pharmacology and toxicology
    55. CHAN JD
      PHARMACOKINETIC DRUG-INTERACTIONS OF VINCA ALKALOIDS - SUMMARY OF CASE-REPORTS

      Pharmacotherapy
    56. KAWASHIRO T; YAMASHITA K; ZHAO XJ; KOYAMA E; TANI M; CHIBA K; ISHIZAKI T
      A STUDY ON THE METABOLISM OF ETOPOSIDE AND POSSIBLE INTERACTIONS WITHANTITUMOR OR SUPPORTING AGENTS BY HUMAN LIVER-MICROSOMES

      The Journal of pharmacology and experimental therapeutics
    57. LEHMANN JM; MCKEE DD; WATSON MA; WILLSON TM; MOORE JT; KLIEWER SA
      THE HUMAN ORPHAN NUCLEAR RECEPTOR PXR IS ACTIVATED BY COMPOUNDS THAT REGULATE CYP3A4 GENE-EXPRESSION AND CAUSE DRUG-INTERACTIONS

      The Journal of clinical investigation
    58. KASHUBA ADM; NAFZIGER AN; KEARNS GL; LEEDER JS; GOTSCHALL R; ROCCI ML; KULAWY RW; BECK DJ; BERTINO JS
      EFFECT OF FLUVOXAMINE THERAPY ON THE ACTIVITIES OF CYP1A2, CYP2D6, AND CYP3A AS DETERMINED BY PHENOTYPING

      Clinical pharmacology and therapeutics
    59. KASHUBA ADM; BERTINO JS; ROCCI ML; KULAWY RW; BECK DJ; NAFZIGER AN
      QUANTIFICATION OF 3-MONTH INTRAINDIVIDUAL VARIABILITY AND THE INFLUENCE OF SEX AND MENSTRUAL-CYCLE PHASE ON CYP3A ACTIVITY AS MEASURED BY PHENOTYPING WITH INTRAVENOUS MIDAZOLAM

      Clinical pharmacology and therapeutics
    60. SEREE E; VILLARD PH; HEVER A; GUIGAL N; PUYOOU F; CHARVET B; POINTSCOMMA H; LECHEVALIER E; LACARELLE B; BARRA Y
      MODULATION OF MDR1 AND CYP3A EXPRESSION BY DEXAMETHASONE - EVIDENCE FOR AN INVERSE REGULATION IN ADRENALS

      Biochemical and biophysical research communications (Print)
    61. ANTTILA S; HUKKANEN J; HAKKOLA J; STJERNVALL T; BEAUNE P; EDWARDS RJ; BOOBIS AR; PELKONEN O; RAUNIO H
      EXPRESSION AND LOCALIZATION OF CYP3A4 AND CYP3A5 IN HUMAN LUNG

      American journal of respiratory cell and molecular biology
    62. THUMMEL KE; KUNZE KL; SHEN DD
      ENZYME-CATALYZED PROCESSES OF FIRST-PASS HEPATIC AND INTESTINAL DRUG EXTRACTION

      Advanced drug delivery reviews
    63. KIVISTO KT; KROEMER HK
      USE OF PROBE DRUGS AS PREDICTORS OF DRUG-METABOLISM IN HUMANS

      Journal of clinical pharmacology
    64. PRESKORN SH; ALDERMAN J; GREENBLATT DJ; HORST WD
      SERTRALINE DOES NOT INHIBIT CYTOCHROME-P450 3A-MEDIATED DRUG-METABOLISM IN-VIVO

      Psychopharmacology bulletin
    65. VONMOLTKE LL; DUAN SX; GREENBLATT DJ; FOGELMAN SM; SCHMIDER J; HARMATZ JS; SHADER RI
      VENLAFAXINE AND METABOLITES ARE VERY WEAK INHIBITORS OF HUMAN CYTOCHROME P450-3A ISOFORMS

      Biological psychiatry
    66. WRIGHT MC; ALLENBY G; PAINE AJ
      EFFECT OF VITAMIN-A-DEFICIENCY ON THE EXPRESSION OF LOW-AFFINITY GLUCOCORTICOID BINDING-SITE ACTIVITY AND GLUCOCORTICOID-DEPENDENT INDUCTION OF CYP3A2 IN RAT-LIVER

      Biochemical and biophysical research communications
    67. KASTRISSIOS H; CHAO NJ; BLASCHKE TF
      PHARMACOKINETICS OF HIGH-DOSE ORAL CCNU IN BONE-MARROW TRANSPLANT PATIENTS

      Cancer chemotherapy and pharmacology
    68. CHRISTIANS U; SCHMIDT G; BADER A; LAMPEN A; SCHOTTMANN R; LINCK A; SEWING KF
      IDENTIFICATION OF DRUGS INHIBITING THE IN-VITRO METABOLISM OF TACROLIMUS BY HUMAN LIVER-MICROSOMES

      British journal of clinical pharmacology
    69. BENET LZ; WU CY; HEBERT MF; WACHER VJ
      INTESTINAL DRUG-METABOLISM AND ANTITRANSPORT PROCESSES - A POTENTIAL PARADIGM SHIFT IN ORAL-DRUG DELIVERY

      Journal of controlled release
    70. LAMPEN A; CHRISTIANS U; BADER A; HACKBARTH I; SEWING KF
      DRUG-INTERACTIONS AND INTERINDIVIDUAL VARIABILITY OF CYCLOSPORINE METABOLISM IN THE SMALL-INTESTINE

      Pharmacology
    71. BERGCANDOLFI M; CANDOLFI E
      DEPRESSION OF THE N-DEMETHYLATION OF ERYTHROMYCIN, AZITHROMYCIN, CLARITHROMYCIN AND CLINDAMYCIN IN MURINE TOXOPLASMA INFECTION

      International journal for parasitology
    72. PAINE MF; SHEN DD; KUNZE KL; PERKINS JD; MARSH CL; MCVICAR JP; BARR DM; GILLIES BS; THUMMEL KE
      FIRST-PASS METABOLISM OF MIDAZOLAM BY THE HUMAN INTESTINE

      Clinical pharmacology and therapeutics
    73. AHONEN J; OLKKOLA KT; SALMENPERA M; HYNYNEN M; NEUVONEN PJ
      EFFECT OF DILTIAZEM ON MIDAZOLAM AND ALFENTANIL DISPOSITION IN PATIENTS UNDERGOING CORONARY-ARTERY BYPASS-GRAFTING

      Anesthesiology
    74. NISHIBE Y; HIRATA M
      INDUCTION OF CYTOCHROME-P450-3A (CYP-3A) BY E-5110, A NONSTEROIDAL ANTIINFLAMMATORY AGENT (NSAID), AND TYPICAL CYP 3A INDUCERS IN PRIMARY CULTURES OF DOG HEPATOCYTES

      Biological & pharmaceutical bulletin
    75. ZANNIKOS PN; BANDYOPADHYAY AM; ROBERTSON LW; BLOUIN RA
      EXPRESSION OF THE CYP3A AND CYP2C11 ENZYMES IN A NUTRITIONALLY OBESE RODENT MODEL - RESPONSE TO PHENOBARBITAL TREATMENT

      International journal of obesity
    76. VONMOLTKE LL; GREENBLATT DJ; COTREAUBIBBO MM; HARMATZ JS; SHADER RI
      INHIBITORS OF ALPRAZOLAM METABOLISM IN-VITRO - EFFECT OF SEROTONIN-REUPTAKE-INHIBITOR ANTIDEPRESSANTS, KETOCONAZOLE AND QUINIDINE

      British journal of clinical pharmacology
    77. CARRIERE V; LESUFFLEUR T; BARBAT A; ROUSSET M; DUSSAULX E; COSTET P; DEWAZIERS I; BEAUNE P; ZWEIBAUM A
      EXPRESSION OF CYTOCHROME-P-450 3A IN HT29-MTX CELLS AND CACO-2 CLONE TC7

      FEBS letters


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/08/20 alle ore 05:04:47